Site Editor

Rebecca Olin, MD, MS


Prognostic Power of Best Responses Under Study in Resistant AML

By: Kayci Reyer
Posted: Friday, February 5, 2021

According to research presented in Blood Advances, patients with relapsed or refractory acute myeloid leukemia (AML) who achieve either complete remission or measurable residual disease negativity may be less likely to experience a relapse. The retrospective study sought to determine the prognostic impact of these milestones and whether they occur independently or as a pair.

“Patients who achieved [complete remission with measurable residual disease negativity] had the best outcomes, which were driven in part by an increased ability to undergo subsequent [hematopoietic stem cell transplantation],” noted Farhad Ravandi, MD, of MD Anderson Cancer Center, Houston, and colleagues.

Data from 141 patients who had undergone first salvage therapy were evaluated. Relapse was less common, and relapse-free survival was superior among patients whose best response was complete remission with full hematologic recovery versus those experiencing incomplete hematologic recovery (P = .01 and P = .004, respectively). However, overall survival was not improved (P = .15). Patients who achieved measurable residual disease negativity experienced similar outcomes in terms of risk of relapse, relapse-free survival, and overall survival versus those for whom residual disease remained detectable (P =.01, P =.05, and P =.21, respectively).

Overall, the best outcomes were associated with patients who achieved both complete remission and measurable residual disease negativity. These patients experienced the highest 2-year overall survival rate (37%) and had the lowest relapse rate. These results may be associated with lower early relapse rates among this group, which appears to be more able to undergo hematopoietic stem cell transplantation. The patient response following such transplantation did not seem to be affected by the response to salvage chemotherapy.

“…Our findings argue against a practice of attempting to administer additional cycles of chemotherapy in an effort to deepen a patient’s response before undergoing hematopoietic stem cell transplantation in the salvage setting,” the investigators commented.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.